Last reviewed · How we verify

Propofol 1%

B. Braun Melsungen AG · FDA-approved active Small molecule

Propofol is a rapid-acting intravenous anesthetic that enhances inhibitory GABA neurotransmission in the central nervous system, producing sedation and unconsciousness.

Propofol is a rapid-acting intravenous anesthetic that enhances inhibitory GABA neurotransmission in the central nervous system, producing sedation and unconsciousness. Used for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units, Sedation for diagnostic and therapeutic procedures.

At a glance

Generic namePropofol 1%
Also known asPropofol-Lipuro 1%, propofol, ANESVAN INJECTION 10MG/ML (PROPOFOL) "CHI SHENG"
SponsorB. Braun Melsungen AG
Drug classIntravenous anesthetic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and hyperpolarizing neuronal membranes. This enhancement of GABAergic inhibition leads to rapid onset of sedation and anesthesia. The drug is highly lipophilic, allowing rapid blood-brain barrier penetration and quick onset/offset of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: